Stoke Therapeutics, a clinical-stage RNA therapeutics company focused on rare genetic diseases, is advancing its lead asset zorevunersen through a global Phase 3 trial. The company’s revenue surged over 400% year-over-year in fiscal 2025, driven by collaboration milestones and licensing income, alongside a marked improvement in operating losses and cash flow. With an expanded corporate footprint and liquidity expected to fund operations into 2028, Stoke is navigating clinical and regulatory complexities amid ongoing FDA interactions. The forthcoming EMPEROR trial data readout in mid-2027 and anticipated New Drug Application submission form the near-term operational focus.